Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 7

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 7
---
 exercise of October 2024 Common Warrants.

Wewill receive the proceeds from any exercise of the Common Warrants for cash. See “Use of Proceeds” beginning on page 44 of this prospectus.

The Selling Stockholders identified in this prospectus, or their pledgees, assignees, donees, transferees or their respective successors-in-interest, from time to time may offer and sell through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices, the shares held by them directly or through underwriters, agents or broker-dealers on terms to be determined at the time of sale, as described in more detail in this prospectus. See “Plan of Distribution” beginning on page 95 of this prospectus for more information about how the Selling Stockholders may sell their respective shares of Common Stock. The Selling Stockholders may be deemed “underwriters” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”).

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “BIAF”. Our Tradeable Warrants are listed on the Nasdaq Capital Market under the symbol “BIAFW”. On June 18, 2025, the last reported sale price of (i) our Common Stock on Nasdaq was $0.2511 per share, and (ii) our Tradeable Warrants on Nasdaq was $0.1451 per Tradeable Warrant. There is no established public trading market for the Non-Tradeable Warrants and we do not expect a market to develop.

Investing in our securities involves risks. You should review carefully the risks and uncertainties described under the heading “ Risk Factors” contained in this prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus, as described beginning on page 8 of this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted.

<div align='center'>The date of this prospectus is , 2025</div>

<div align='center'>TABLE OF CONTENTS</div>

| ABOUT THIS PROSPECTUS                                                                  |  ii |
| PROSPECTUS SUMMARY                                                                     |   1 |
|